PolyPid Ltd. (PYPD) Reports Q1 Loss of $0.28/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 10, 2023 7:00 AM EDTSubmitted Revised Protocol for SHIELD II Phase 3 Trial to FDA to Evaluate D-PLEX100Â for Prevention of Abdominal Colorectal Surgical Site Infections; Recruitment Expected to Resume Imminently
Received Advice from the Swedish Medical Products Agency Consistent with Feedback Received from the FDA
Completed a Series of Transactions to Further Solidify Financial Position and Extend Cash Runway to Late in Q1 2024
... More